CLSD — Clearside Biomedical, Inc.

Clearside Biomedical Q4 2024 Earnings Call Summary

1. Key Financial Results and Metrics

• As of December 31, 2024, Clearside Biomedical reported cash and cash equivalents of approximately $20 million.
• The company believes it has sufficient resources to fund operations into Q4 2025.
• Plans to explore funding options for the CLS-AX Phase 3 program, including potential partnerships.

2. Strategic Updates and Business Highlights

• Clearside continues to lead in the delivery of drugs to the suprachoroidal space, with over 15,000 injections performed using their SCS Microinjector.
• Positive results from the ODYSSEY Phase 2b trial for CLS-AX in wet AMD led to a successful end of Phase 2 meeting with the FDA, aligning on a pivotal Phase 3 program.
• Strategic partnerships are advancing, with Arctic Vision achieving regulatory milestones in Asia and REGENXBIO planning a global Phase 3 program for diabetic retinopathy using the SCS Microinjector.
• The company is also exploring opportunities in geographic atrophy with small molecule treatments.

3. Forward Guidance and Outlook

• The Phase 3 trial for CLS-AX is expected to start in the second half of 2025, with an enrollment period anticipated to be around 12 months.
• The trial will focus on treatment-naive patients to potentially improve outcomes and reduce variability.
• The company aims to position CLS-AX as a leading maintenance treatment in the wet AMD market, which has a significant commercial opportunity estimated at over $12 billion annually.

4. Bad News, Challenges, or Points of Concern

• The company faces the challenge of funding the Phase 3 trial, which may require partnerships or other financing strategies.
• Concerns were raised about the variability in patient responses and the potential impact on enrollment speed due to strict inclusion criteria.
• The competitive landscape remains intense, with other companies pursuing similar treatments, necessitating a strong differentiation strategy for CLS-AX.

5. Notable Q&A Insights

• Analysts inquired about the expected enrollment timeline for the Phase 3 trial, with management estimating around 12 months.
• The cost of the Phase 3 program was discussed, with estimates for similar trials ranging around $55 million to $60 million, though Clearside did not provide specific figures.
• The company clarified its redosing criteria, emphasizing the use of OCT biomarkers and the differentiation between redosing and rescue criteria, which could impact regulatory risk and trial outcomes.
• Management expressed confidence that the design of the Phase 3 trial would not significantly hinder market adoption, as they anticipate that the strict criteria will lead to more reliable data.

Overall, Clearside Biomedical is positioned to advance its innovative suprachoroidal delivery platform, with a focus on wet AMD and other retinal diseases, while navigating funding and competitive challenges ahead.